Literature DB >> 1387231

Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations.

T A Marsen1, M Pollok, K Oette, C A Baldamus.   

Abstract

An in vivo comparison of three dosages (3 g, 6 g, 12 g) of two different fish oil preparations in terms of plasma concentrations of their major active components eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was performed. The plasma accumulation was measured during 28 days of ingestion and an equally long wash out period. Data were scrutinized for bioavailability in order to distinguish between the efficiency of the two preparations. Rapid increases in EPA and DHA plasma concentrations can be demonstrated at all dosages during a 28-day ingestion period. EPA accumulated more during ingestion of high than of low dosages of fish oil. DHA revealed almost identical increases and peak values in plasma concentrations in all subgroups. The present data demonstrate dose dependent increases of EPA concentrations whereas DHA plasma concentrations are comparable in all dosages investigated. Measurable EPA and DHA plasma concentration levels are inappropriate means to explain clinical effectiveness. These results were found in both commercially available fish oil preparations. Direct comparison of both preparations revealed no differences in bioavailability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387231     DOI: 10.1016/0952-3278(92)90069-u

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

1.  Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids.

Authors:  Susanna L Lundström; Jun Yang; John D Brannan; Jesper Z Haeggström; Bruce D Hammock; Parameswaran Nair; Paul O'Byrne; Sven-Erik Dahlén; Craig E Wheelock
Journal:  Mol Nutr Food Res       Date:  2013-07-04       Impact factor: 5.914

2.  Pharmacokinetics of omega-3 fatty acids in patients with severe sepsis compared with healthy volunteers: A prospective cohort study.

Authors:  Radhika Parikh; Jason H T Bates; Matthew E Poynter; Benjamin T Suratt; Polly E Parsons; C Lawrence Kien; Daren K Heyland; Karen I Crain; Julie Martin; Jayanthi Garudathri; Renee D Stapleton
Journal:  Clin Nutr       Date:  2019-04-09       Impact factor: 7.324

3.  Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis.

Authors:  L Shinto; G Marracci; S Baldauf-Wagner; A Strehlow; V Yadav; L Stuber; D Bourdette
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-01-25       Impact factor: 4.006

4.  Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.

Authors:  Antonio Rusca; Andrea Francesco Daniele Di Stefano; Mira V Doig; Claudia Scarsi; Emilio Perucca
Journal:  Eur J Clin Pharmacol       Date:  2009-01-16       Impact factor: 2.953

5.  Marine lipid-based liposomes increase in vivo FA bioavailability.

Authors:  Maud Cansell; Fabienne Nacka; Nicole Combe
Journal:  Lipids       Date:  2003-05       Impact factor: 1.880

6.  The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis.

Authors:  Lynne Shinto; Gail Marracci; Lauren Bumgarner; Vijayshree Yadav
Journal:  Autoimmune Dis       Date:  2011-07-20

7.  Safety of a novel feed ingredient, Algal Oil containing EPA and DHA, in a gestation-lactation-growth feeding study in Beagle dogs.

Authors:  Irina Dahms; Eileen Bailey-Hall; Erin Sylvester; Audrey Parenteau; Shiguang Yu; Alexios Karagiannis; Franz Roos; Jon Wilson
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.